China National Medical Products Administration grants approval of Roche ’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer

Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).“Small cell lung cancer is an area of major unmet need in China and one that has seen limited advances until now,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “This approval makes Tecentriq the first cancer immunotherapy available in China for the initial treatment of extensive-stage small cell lung cancer less than a year after the US FDA and EMA approvals, marking a swift and important step forward for patients with this aggressive and difficult-to-treat disease.” Lung cancer is the most common cancer and the leading cause of cancer death in China.1 Overall, SCLC accounts for around 15% of all lung cancer cases and, with two-thirds of patients diagnosed at the ‘extensive’ stage, the prognosis for people with this form of the disease is poor.2 The average five-year survival for people with ES-SCLC is only 2%.3 This approval is based on results from the Phase III IMpower133 study, which showed that Tecentriq in combination with chemotherapy helped people live significantly longer compared with chemotherapy alone (median overall survival [OS]=12.3 versus 10...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news

Related Links:

Authors: Zhou S, Wei J, Wang Y, Liu X Abstract Hepatocellular carcinoma (HCC) is a leading cause of cancer-associated mortality worldwide. Despite clinical advances, the survival rate of patients with HCC remains low, as most patients are diagnosed with HCC when they are already at the advanced stage. Certain circular RNAs (circRNAs) are closely associated with the development of liver cancer. In the present study, a circRNA array was performed to screen differentially expressed circRNAs in HCC tissues. The further analysis focused on the newly identified circRNA_101237, the host gene of which, cyclin-dependent kin...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
Authors: Li L, Zheng Y, Zheng Q, Jiang J Abstract The present study aimed to investigate the antiproliferative effect of embryonic stem cell-conditioned medium (ESC-CM) on the mouse liver cancer Hepa1-6 cells in vitro. Furthermore, in order to elucidate the underlying molecular mechanism, the microRNAs (miRNAs) in ESC-CM associated with the inhibition of Hepa1-6 proliferation were identified. Following the co-culture of ESC-CM and Hepa1-6 in Transwell chambers, the proliferation, cell cycle, apoptosis and associated protein expression were determined in Hepal-6 cells. Moreover, miRNA array analysis was employed to ...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
In spite of the recent approval of new promising targeted therapies, the clinical outcome of patients with acute myeloid leukemia (AML) remains suboptimal, prompting the search for additional and synergistic therapeutic rationales. It is increasingly evident that the bone marrow immune environment of AML patients is profoundly altered, contributing to the severity of the disease but also providing several windows of opportunity to prompt or rewire a proficient antitumor immune surveillance. In this Review, we present current evidence on immune defects in AML, discuss the challenges with selective targeting of AML cells, an...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
Trump says personal protective gear has nearly run out; Florida, Georgia, Mississippi ordered to shelter in place; record daily fatalities in UK. Follow the latest updates.At a glance: summary of key eventsWimbledon cancelled due to coronavirus crisisAustralia coronavirus – latest updatesSee all of our coronavirus coverage5.54amBSTThe Chinese city of Shenzhen has banned the eating of dogs and cats as part of a wider clampdown on the wildlife trade since the emergence of the new coronavirus, Reuters reports.Scientists suspect the coronavirus passed to humans from animals. Some of the earliest infections were found in ...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Coronavirus outbreak UK news World news Science Infectious diseases Middle East and North Africa South Africa Russia China Japan Asia Pacific Europe Medical research Microbiology Source Type: news
Bacteria in some tumors may hinder cancer treatments. (read more)
Source: Environmental Factor - NIEHS Newsletter - Category: Environmental Health Source Type: news
Publication date: Available online 1 April 2020Source: LinguaAuthor(s): Cai-Mei Yang, Tiao-Yuan Mao, Bing Bai
Source: Lingua - Category: Speech-Language Pathology Source Type: research
Publication date: Available online 31 March 2020Source: Actas Urológicas Españolas (English Edition)Author(s): D. Nieblas-Toscano, A.J. Arenas-Bonilla, J.F. Flores-Martín, F. Gutiérrez-Tejero, C. Velarde-Muñoz, C.I. Ramos-Alaminos, M.C. Salas-Moreno, R. Galisteo-Moya, J. Moreno-Jiménez
Source: Actas Urologicas Espanolas - Category: Urology & Nephrology Source Type: research
This report provides an in-depth look at public drug program spending in Canada, using the Canadian Institute for Health Information's (CIHI) National Prescription Drug Utilization Information System. Public drug program spending does not include spending on drugs dispensed in hospitals or on those funded through cancer agencies and other special programs. Public drug program spending increased by 6.8% in 2018, compared to an increase of 5.3% in 2017. The growth in 2018 was largely because of the introduction of Ontario Health Insurance Plan+ (OHIP+), which extended drug coverage to all Ontario residents age 24 years or y...
Source: Healthcare Quarterly - Category: International Medicine & Public Health Source Type: research
This article analyzes data on 28 indicators prioritized over these years and demonstrates that 25 have shown sustained improvement over time. The performance management approach, lessons learned and gaps in knowledge are described to inform future research and practice.
Source: Healthcare Quarterly - Category: International Medicine & Public Health Source Type: research
Publication date: Available online 31 March 2020Source: Preventive MedicineAuthor(s): Dean Connolly, Xan Hughes, Alison Berner
Source: Preventive Medicine - Category: International Medicine & Public Health Source Type: research
More News: Avastin | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | China Health | Gastroenterology | Grants | Head and Neck Cancer | Hepatocellular Carcinoma | Immunotherapy | Liver | Liver Cancer | Lung Cancer | OBGYN | Pharmaceuticals | Skin | Small Cell Lung Cancer | Statistics | Study | Urology & Nephrology